HealthCare Global Enterprises Limited (HCG), India’s leading provider of cancer care, has announced a research collaboration with Trucan Diagnostics Pvt Ltd, a pioneering startup specializing in advanced cancer diagnostics. This partnership aims to validate a suite of novel diagnostic tests designed to improve detection of primary and recurrent/metastatic cancer precisely, predict therapy responses, and monitor treatment efficacy.
Under this partnership, HCG and Trucan will work together to conduct extensive validation studies on a new set of cancer diagnostic tests developed by Trucan. These tests employ advanced techniques, including next-generation sequencing and novel biomarker-driven diagnostics, to enable precise primary, recurrent/metastatic cancer detection, pre-treatment prediction of response to therapy, and monitoring patients undergoing chemo or targeted therapy.
Dr. B. S. Ajaikumar, Executive Chairman, Healthcare Global Enterprises Limited, commented, “At HCG, our mission has always been to lead with innovation and compassion, especially in the fight against cancer.” Adding to this, Dr. Raman Govindarajan, Founder & CEO of Trucan Diagnostics, said, “Partnering with HCG gives us a tremendous opportunity to validate our novel diagnostic solutions in a real-world setting.”
